- NewAmsterdam Pharma to Present New Analysis from the Phase 2 ROSE2 Trial Evaluating Obicetrapib in Combination with Ezetimibe at 2024 American College of Cardiology Congress
- NewAmsterdam Pharma Doses First Patient in Phase 3 TANDEM Clinical Trial Evaluating Fixed-Dose Combination of Obicetrapib and Ezetimibe in Patients with HeFH and/or ASCVD
- NewAmsterdam Pharma Reports Full Year 2023 Financial Results and Provides Corporate Update
- NewAmsterdam Pharma to Participate in Upcoming Investor Conferences in March
- NewAmsterdam Pharma Announces Pricing of $175.3 Million Public Offering of Ordinary Shares and Pre-Funded Warrants
- NewAmsterdam Pharma Announces Commencement of Public Offering of Ordinary Shares and Pre-Funded Warrants
- NewAmsterdam Pharma to Present at Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
- NewAmsterdam Pharma Appoints William H. Lewis, J.D., M.B.A. as Chair of its Board of Directors
- NewAmsterdam Pharma Announces 2024 Strategic Priorities
- NewAmsterdam Pharma Provides Corporate Update and Reports Third Quarter 2023 Financial Highlights
More ▼
Key statistics
As of last trade NewAmsterdam Pharma Company NV (NAMS:NMQ) traded at 23.58, -10.53% below its 52-week high of 26.35, set on Jan 25, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 22.42 |
---|---|
High | 23.61 |
Low | 22.26 |
Bid | 23.43 |
Offer | 23.71 |
Previous close | 22.70 |
Average volume | 113.04k |
---|---|
Shares outstanding | 89.27m |
Free float | 77.09m |
P/E (TTM) | -- |
Market cap | 2.03bn USD |
EPS (TTM) | -2.74 USD |
Data delayed at least 15 minutes, as of Mar 28 2024 15:40 BST.
More ▼